

**Division of Health Care, Quality, Financing and Purchasing
Center for Operations and Pharmacy Management
Pharmacy and Therapeutics Committee Meeting Minutes**

Tuesday April 8, 2008

8:00 AM

EDS

**171 Service Avenue Building 1 Suite 100
Warwick, Rhode Island**



P&T Members Present:

Tara Higgins, RPh, CGP, CDOE
Kristina Ward, Pharm D
David Feeney, RPh, Chairperson
Gregory Allen, MD
L. McIntyiere Johnston, MD
Richard Wagner, MD
Charles Gross

Others Present:

Paula Avarista, RPh, MBA (RI Medical Assistance Program)
Ray Maxim, MD (RI Medical Assistance Program)
Mary Ann Murray, RN (Electronic Data Systems)
Karen Mariano, RPh (Electronic Data Systems)
Ann Bennett (Electronic Data Systems)
Chris Andrews, Pharm D (Coventry Health Systems)
Raquel Holmes, RPh (Coventry Health Systems)

The meeting was called to order by Chairperson Feeney at 8:08 AM. After welcoming and introductory remarks, the meeting minutes of the December 4, 2007 meeting were reviewed. All members voted in favor to accept the minutes as presented. The public comment portion of the meeting began. Representatives from the following Pharmaceuticals Manufacturing Companies gave presentations: Schering-Plough, Eli Lilly, Sanofi-Aventis, Roche, Biogen IDC, Amylin, Allergan, EMD Serono, Astra-Zeneca, Daiichi-Sankyo, Novo Nordisk, GlaxoSmithKline, Takeda, TAP, Pfizer, and Merck & Co. Also presentations were given Dr. Barbara Roberts, Dr. David Pomerantz and Gwen Reene.

Raquel Holmes, the new RI account manager for Coventry Health Systems, gave an overview of the first year of the program. The target of 85% compliance with the PDL was reached in the majority of the classes. Those drug classes where there was either grandfathering for existing beneficiaries for non-preferred drugs or small utilization within a class contributed to not reaching the 85% compliance. Chris Andrews and Raquel Holmes from Coventry Health Systems gave an overview of the drug classes that were on the agenda to be reviewed. A discussion among the committee members followed each class review. Voting took place at the end of each review. Ten drug classes were up for re-review. No changes were made in those classes. The committee voted in favor of the recommendations from Coventry. Growth Hormones were again reviewed. The committee voted in favor of the recommendations. Other new drug classes reviewed were Multiple Sclerosis agents, Acne agents and NSAID Ophthalmic agents. The committee voted in favor of the recommendations from First Health. The meeting adjourned at 10:45. The next meeting is June 3, 2008.